Joseph Monahan - 01 Sep 2021 Form 4 Insider Report for Aclaris Therapeutics, Inc. (ACRS)

Role: Chief Scientific Officer
Signature: /s/ Mark Ballantyne, Attorney-in-Fact
Issuer symbol: ACRS
Transactions as of: 01 Sep 2021
Net transactions value: -$17,926
Form type: 4
Filing time: 02 Sep 2021, 17:39:28 UTC
Previous filing: 02 Jun 2021
Next filing: 03 Feb 2022
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	ACRS	Common Stock	Options Exercise		+2,333	+2.7%		87,675	01 Sep 2021	Direct	F1
transaction	ACRS	Common Stock	Tax liability	$17,926	-1,041	-1.2%	$17.22	86,634	01 Sep 2021	Direct	F2
holding	ACRS	Common Stock						193	01 Sep 2021	By Spouse

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	ACRS	Restricted Stock Units	Options Exercise	$0	-2,333	-100%	$0.000000^*	0	01 Sep 2021	Common Stock	2,333		Direct	F1, F3

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer.
F2	The transaction reported represents the withholding of shares by the issuer to satisfy the Reporting Person's tax withholding obligations in connection with the vesting and settlement of restricted stock units described in this Form 4.
F3	The shares underlying these restricted stock units vested on September 1, 2021.